The RANTES increase was significantly lower in the treated groups compared to the BD group: Coversin group 1004 pg/mL (331–1677) (p < 0.0001), anti-CD14 group 267 pg/mL (75–460) (p < 0.0001) and the dual treatment group 420 pg/mL (107–733) (p = 0.001) (Fig. 3B). The gene discussed is CCL5; the disease is Behcet disease.